VEGFA and glioblastoma: Interestingly, either pharmacological inhibition or genetic deletion of PDGF receptor sensitizes VEGF/VEGFR-2-directed therapy in a mouse GBM model, suggesting that targeting Endo-MT by PDGF inhibition may offer promising opportunities for overcoming anti-VEGF resistance in tumors.